Project Grant R01DA064139
Award Date 9/1/25
Completion Date 5/31/30
Dollars Obligated $1.8M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This $1,144,344 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop a novel gene therapy approach to eliminate the HIV/SIV reservoir in the central nervous system of methamphetamine-exposed rhesus macaques on antiretroviral therapy. The research will use a specialized AAV vector (R2MAC) capable of penetrating the blood-brain barrier to deliver multiplex CRISPR/Cas editors targeting the viral...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $687,416 Project Grant to the J. David Gladstone Institutes in San Francisco, California. The grant is for a research project titled "Targeted Small Molecule Recruitment to Suppress the HIV Transcriptionally Active Reservoir" and runs from May 15, 2025 to March 31, 2030. The key objectives of this research project are to develop therapeutically effective...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $703,675 Project Grant (CFDA 93.279) to the University of North Carolina at Chapel Hill (UNC-CH) for the project "Transcriptional Inactivation of the CNS HIV Reservoir with Tat-Targeting Lipid Nanoparticles." This grant aims to develop lipid nanoparticles containing gene-editing tools that can inactivate the HIV Tat gene in microglial cells, the primary HIV reservoir in the central...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $558,668 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Massachusetts Institute of Technology (MIT) for the project "Integration and Validation of Single-Cell Neuronal and Immune Molecular Responses in SUD and HIV". The project aims to uncover the genetic and molecular mechanisms driving the interactions between HIV, neuropsychiatric, and...
- This federal Project Grant award, valued at $563,742.00, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research to investigate the impact of HIV infection and cocaine use on lipid metabolism in microglia, a type of brain cell, and the role this plays in the development of neurological symptoms associated with HIV (referred to as NeuroHIV). Key research activities include: Examining how HIV proteins...
- The National Institute on Drug Abuse (NIDA), under CFDA Program 93.279 - Drug Use and Addiction Research Programs, awarded a $1 project grant to the J. David Gladstone Institutes. The grant aims to establish a novel mouse model for studying the impact of HIV and addictive substances on the central nervous system. Specifically, the project will develop a chimeric mouse model with human microglia, neurons, and astrocytes derived from induced pluripotent stem cells. This model will be used to...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $608,652 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Scripps Research Institute. The purpose of this 5-year award, with a start date of September 1, 2025, is to conduct data mining and functional validation of the Systematic Characterization of Retroviral Conditions for Health (SCORCH) datasets. The research aims to elucidate the key pathogenic...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,025,015 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Scintillon Institute in California. The grant, awarded on August 11, 2025, supports the development of a next-generation preclinical model of NeuroHIV that better recapitulates the neuro-immune-vascular system interactions in the context of antiretroviral therapy-mediated HIV suppression....
- This $616,372 federal Project Grant was awarded on July 15, 2025 by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research to identify neuronal, glial, and neural stem/progenitor cell transposable element (TE) transcriptional and epigenetic gene regulatory states involved in SIV, antiretroviral therapy, and cannabinoid exposure in a non-human primate model. Additionally, the research aims to identify TE expression...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $698,390 to the Regents of the University of California at Riverside to conduct research aimed at harnessing innate immunity to control the neuroinflammatory HIV reservoir. The key objectives are to investigate how HIV infection triggers an interferon (IFN) response, how HIV...